Compare Abbott Laboratories (ABT) vs Centrus Energy Corp (LEU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Centrus Energy Corp — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Centrus Energy Corp trades at $166 (market cap $3.26B). The key difference: Abbott Laboratories is far larger — about 51.2× Centrus Energy Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| ABT | LEU | |
|---|---|---|
Market Cap | $166.94B | $3.26B |
Sector | Health | Energy |
52-Week High | $136.62 | $436.00 |
52-Week Low | $82.57 | $146.61 |
Enterprise Value | $193.69B | $2.57B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Centrus Energy (LEU) trades at $174.23, up 7.46% today, with mixed technical signals showing neutral momentum. The company reported strong Q1 2026 earnings beat but faces valuation concerns with a P/E of 63.36. Recent catalysts include a $900 million DOE contract and inclusion in the S&P SmallCap 600 index, positioning LEU as the sole U.S.-licensed HALEU producer amid growing nuclear energy demand.
LEU offers exposure to U.S. nuclear fuel supply chain growth with $3.9 billion contracted backlog, but high valuation and execution risks warrant caution. Analyst consensus targets $219.50 (26% upside) with no sell ratings, though recent earnings misses and declining 2026 profit margins highlight operational challenges. The stock's premium valuation requires sustained contract execution and margin improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
